All Blogs

Sep 06, 2023

Chronic pain is an unwelcome companion in the journey of life and can significantly impact the quality of life. Being in pain serves as a protective mechanism that warns us when something is wrong with the concerned body part, and is a natural component of the human experience. But for millions of people around the...

Sep 05, 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...

Sep 04, 2023

Fabry disease is a rare hereditary lysosomal storage disorder that is caused by mutation in the GLA gene located on the X chromosome. The defect leads to the deficiency of an enzyme called alpha-galactosidase A, responsible for the breakdown of globotriaosylceramide (Gb3). The accumulation of the fatty substance le...

Sep 24, 2024

The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...

Aug 31, 2023

GE HealthCare Launched CardioVisio for Atrial Fibrillation, a Digital, Patient-Centric Clinical Decision Support Tool to Enable Precision Care On August 24, 2023, GE HealthCare launched CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relev...

Aug 30, 2023

In recent years, the rapid development of technology and innovation has sped up the transformation of the healthcare and well-being industry. Among the various emerging and evolving trends, Light Therapy is one of the key technologies gaining immense attention among the users. Light Therapy is an ancient practice, ...

Aug 29, 2023

FDA Approves Bristol Myers Squibb’s Reblozyl as First-Line Treatment of Anemia in Adults with Lower-Risk MDS Who May Require Transfusions Bristol Myers Squibb announced that the Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia in adult patients with very l...

Jul 24, 2024

Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the FDA has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are approved for oncology indications, ...

Aug 25, 2023

Homozygous familial hypercholesterolemia (HoFH) is a rare form of familial hypercholesterolemia, an autosomal-dominant genetic disorder of lipid metabolism characterized by strikingly elevated levels of low-density lipoprotein cholesterol (LDL-C).  Heterozygous Familial Hypercholesterolemia vs. Homozygous F...

Aug 24, 2023

Smith+Nephew Launched Hip Arthroplasty System in India  On August 17, 2023, The London-based orthopedic device maker Smith+Nephew announced the launch of its OR3O dual mobility system for use in primary and revision hip arthroplasty in India. The dual mobility implants have a smaller-diameter femoral hea...